logo

For the Inventor, By the Inventor

Tromso, Norway

Lytix Biopharma as

Calculating rank
USPTO Granted Patents = 17

% Expired Patents = 47.1



Forward Citations = 34

Loading Chart...
Loading Chart...

29 inventors (with patents filed for the assignee):

goldMedal John Sigurd Svendsen (13 out of 17 patents)

silverMedal Øystein Rekdal (9 out of 11 patents)

bronzeMedal Wenche Stensen (8 out of 10 patents)

4.  Oystein Rekdal (6 out of 7 patents)

5.  Bengt Erik Haug (4 out of 4 patents)

6.  Baldur Sveinbjørnsson (4 out of 4 patents)

7.  Liv Marie Eike (3 out of 3 patents)

8.  John Sigurd Mjoen Svendsen (3 out of 3 patents)

9.  Morten Bøhmer Strøm (3 out of 4 patents)

10.  Istvan Marko (3 out of 3 patents)

11.  Merete Linchausen Skar (3 out of 3 patents)

12.  Frederick Alan Leeson (3 out of 4 patents)

13.  Laurence Zitvogel (2 out of 24 patents)

14.  Ketil Camilio (2 out of 2 patents)

15.  Baldur Sveinbjornsson (2 out of 2 patents)


17 patents:

1. 12239686 - Immune checkpoint inhibitor combinations (2025-03-04),
2. 11123398 - Chemotherapeutic combinations of cationic antimicrobial peptides and chemotherapeutics (2021-09-21),
3. 11083774 - Immune checkpoint inhibitor combinations (2021-08-10),
4. 10231954 - Neurodegenerative therapies (2019-03-19),
5. 9556223 - Antimicrobial compounds (2017-01-31),
6. 9241968 - Nonapeptide with anti-tumour activity (2016-01-26),
7. 9212202 - Methods of peptide modification (2015-12-15),
8. 9115169 - Method of treating tumors (2015-08-25),
9. 9109048 - Inhibition of tumor growth (2015-08-18),
10. 9085608 - Treatment of biofilms (2015-07-21),
11. 8809280 - Therapeutic peptides (2014-08-19),
12. 8598114 - Antimicrobial compounds (2013-12-03),
13. 8283315 - Inhibition of tumour growth (2012-10-09),
14. 8143211 - Bioactive peptides (2012-03-27),
15. 8048852 - Antimicrobial compounds and formulations (2011-11-01),
Company Overview
Lytix Biopharma AS is a biopharmaceutical company based in Tromso, Norway, focused on developing innovative therapies for cancer treatment. The company specializes in the design and manufacture of peptide-based compounds that harness the immune system to target and destroy cancer cells. Lytix's research emphasizes the intersection of immunotherapy and oncology, aiming to enhance patient outcomes through novel treatment modalities. Their commitment to advancing cancer care positions them as a key player in the biopharmaceutical landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

17 Patents

#2 in Tromso

#92 in Norway

#35,948 in the World

Tromso, NO
Tromso, Norway

Lytix Biopharma as

Forward Citations = 34

29 inventors:

goldMedal John Sigurd Svendsen (13 out of 17 patents)

silverMedal Øystein Rekdal (9 out of 11 patents)

bronzeMedal Wenche Stensen (8 out of 10 patents)

4.  Oystein Rekdal (6 out of 7 patents)

5.  Bengt Erik Haug (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Lytix Biopharma as. Retrieved from https://idiyas.com/company/lytix-biopharma-as

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…